Free Trial

Prime Medicine (PRME) Competitors

Prime Medicine logo
$4.07 -0.01 (-0.25%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$4.06 -0.02 (-0.37%)
As of 09/12/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRME vs. APGE, CDTX, BEAM, TWST, BHVN, IMCR, AUPH, TVTX, ARDX, and WVE

Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Biohaven (BHVN), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Ardelyx (ARDX), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

Prime Medicine vs. Its Competitors

Prime Medicine (NYSE:PRME) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, Apogee Therapeutics had 9 more articles in the media than Prime Medicine. MarketBeat recorded 12 mentions for Apogee Therapeutics and 3 mentions for Prime Medicine. Apogee Therapeutics' average media sentiment score of 1.32 beat Prime Medicine's score of 0.26 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apogee Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Apogee Therapeutics has lower revenue, but higher earnings than Prime Medicine. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.96M110.40-$198.13M-$1.56-2.61
Apogee TherapeuticsN/AN/A-$182.15M-$4.13-8.93

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Prime Medicine has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Prime Medicine presently has a consensus target price of $8.92, suggesting a potential upside of 119.08%. Apogee Therapeutics has a consensus target price of $97.29, suggesting a potential upside of 163.79%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Apogee Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Apogee Therapeutics' return on equity of -34.65% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime MedicineN/A -107.87% -74.97%
Apogee Therapeutics N/A -34.65%-32.76%

Summary

Apogee Therapeutics beats Prime Medicine on 10 of the 15 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRME vs. The Competition

MetricPrime MedicineBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$547.72M$287.04M$5.86B$21.59B
Dividend YieldN/AN/A5.68%3.48%
P/E Ratio-1.99N/A75.2029.75
Price / Sales110.40420.31514.9786.32
Price / CashN/A22.4437.5625.00
Price / Book2.9710.9112.154.58
Net Income-$198.13M-$111.61M$3.29B$999.94M
7 Day Performance9.41%-0.34%0.75%0.68%
1 Month Performance6.82%3.23%4.82%3.10%
1 Year Performance-0.49%-16.04%60.59%14.39%

Prime Medicine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRME
Prime Medicine
3.2911 of 5 stars
$4.07
-0.2%
$8.92
+119.1%
+0.5%$547.72M$4.96M-1.99234
APGE
Apogee Therapeutics
2.928 of 5 stars
$36.37
-0.7%
$97.29
+167.5%
-25.0%$1.68BN/A-8.8191News Coverage
Positive News
CDTX
Cidara Therapeutics
3.2774 of 5 stars
$65.39
+0.2%
$64.14
-1.9%
+478.1%$1.66B$1.27M-5.8890Positive News
BEAM
Beam Therapeutics
2.8753 of 5 stars
$16.36
-2.9%
$48.45
+196.2%
-15.6%$1.66B$60.27M-3.64510
TWST
Twist Bioscience
3.9726 of 5 stars
$26.97
+1.4%
$49.40
+83.2%
-43.2%$1.63B$362.27M-18.60990News Coverage
BHVN
Biohaven
3.2792 of 5 stars
$15.35
-1.1%
$54.23
+253.2%
-61.0%$1.62BN/A-2.00239Trending News
Gap Down
IMCR
Immunocore
1.8645 of 5 stars
$32.22
-0.1%
$56.89
+76.6%
+6.7%$1.62B$356.15M-80.55320
AUPH
Aurinia Pharmaceuticals
2.9246 of 5 stars
$11.99
-0.7%
$12.00
+0.1%
+93.6%$1.58B$235.13M27.88300News Coverage
Positive News
TVTX
Travere Therapeutics
2.995 of 5 stars
$17.50
-1.1%
$33.43
+91.0%
+86.3%$1.56B$333.87M-8.58460News Coverage
Analyst Forecast
ARDX
Ardelyx
4.6288 of 5 stars
$6.36
-0.3%
$11.50
+80.8%
+6.3%$1.53B$333.61M-27.6590News Coverage
Positive News
WVE
WAVE Life Sciences
4.555 of 5 stars
$9.60
-3.3%
$20.27
+111.1%
+18.9%$1.53B$108.30M-10.67240Positive News

Related Companies and Tools


This page (NYSE:PRME) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners